Clinical Trials

Phase I Multicenter, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose For Trichostatin A In Subjects With Relapsed Or Refractory Hematologic Malignancies


Study ID
Vanda VP-VTR-297-1101

NCT Number
Pending (Click on the NCT number for more information about the trial)

Research Study Number
2018-0050

Principle Investigator
Dr. David Vesole

Phase
I

Sponsor
Vanda Pharmaceuticals


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now